共 50 条
- [1] Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study [J]. LANCET NEUROLOGY, 2023, 22 (05): : 383 - 394
- [6] Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study [J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17
- [8] PRELIMINARY-RESULTS OF A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF CYCLOSPORINE IN MYASTHENIA-GRAVIS [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (12): : 719 - 724
- [9] Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis ( MycarinG): a randomised, double- blind, placebo- controlled, adaptive phase 3 study (vol 22, pg 383, 2023) [J]. LANCET NEUROLOGY, 2023, 22 (10): : E11 - E11